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Abstract: In this review, we provide an overview of the 
relationship between cannabis use and the development 
of schizophrenia, using both animal and human stud-
ies. We further discuss the potential neural mechanism 
that may mediate the relationship between cannabis use 
and schizophrenia symptoms. We finally provide clinical 
implications and future studies that can further elucidate 
the relationship between cannabis and schizophrenia.
Keywords: cannabis; endocannabinoid receptors; nega-
tive symptoms; positive symptoms; schizophrenia.
Introduction
Schizophrenia is one of the most common neurodevelop-
mental disorders (Khandaker et al., 2011). It is manifested 
with various symptoms including positive (hallucina-
tions, delusions, and though disorder), negative (loss of 
motivation, anhedonia, and lack of affect), and cognitive 
deficits (Kohen, 2004) as well as metabolic abnormalities 
(McEvoy et  al., 2005). Adolescence is a period with spe-
cific psychosocial challenges and changes in the brain 
that may be associated with an increase in the probability 
of substance abuse (van Nimwegen et al., 2005). The Diag-
nostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5) states that the onset of schizophrenia 
typically occurs between the late teens and the mid-30s. It 
is apparent that some aspects of the disorder are observed 
during the early adolescent period before an individual 
presents with a full spectrum of schizophrenia symptoms 
(Maki et  al., 2005). Schizophrenia is considered to be a 
neurodevelopmental disorder (Weiser et al., 2004) with its 
pathogenesis stretching back to gestation and early child-
hood (Cannon and Murray, 1998).
There is a growing interest in the link between schizo-
phrenia and substance abuse. Substance abuse comorbid-
ity is a common problem for patients with schizophrenia 
and related psychotic disorders (Fowler et al., 1998). Glass-
man (1993) suggested that apathy and lack of motivation, 
which is a characteristic of negative symptoms in schiz-
ophrenia, is what one would expect with diminishing 
activity of the brain’s reward system. It is suggested that 
the increase in dopaminergic activity, which mediates 
positive reinforcement, is the basis of this self-medication 
hypothesis. Previous studies have estimated that up to 
60% of people with schizophrenia have comorbid sub-
stance abuse (Fowler et al., 1998; Margolese et al., 2004). 
In another study, schizophrenia patients in comparison 
to the healthy population have been found to have a two-
fold increase in rates of cannabis use. Further, it has been 
found that cannabis is the most commonly used illicit 
drug among patients with schizophrenia, with a 64.4% 
lifetime use (Barnes et  al., 2006). Koskinen et  al. (2010) 
found that approximately 25% of patients with schizo-
phrenia have been diagnosed with a comorbid cannabis 
use disorder (CUD).
Previous work has shown that among people with 
schizophrenia life expectancy is estimated to be 20% 
less than in the general population (Mortensen and Juel, 
1993; McCreadie and Kelly, 2000). The use and abuse of 
alcohol, marijuana, psychostimulants, and other drugs 
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is commonly found to be comorbid with psychiatric con-
ditions in adolescents (Deas and Brown, 2006). Specifi-
cally, cannabis use among patients with schizophrenia 
is approximately 10 times higher than in the global popu-
lation (Koskinen et al., 2009) with a lifetime abuse ratio 
of five or six times higher than the general population 
(Regier et al., 1990). Furthermore, there is an inverse cor-
relation between the amount of cannabis use in adoles-
cence and the age of onset of psychosis (Large et al., 2011). 
Importantly, early onset psychosis also occurs alongside 
deficits in cognitive control (Solowij and Michie, 2007), 
more severe course of symptoms, and poorer treatment 
outcomes (Clausen et al., 2013).
Evidence suggests that the intravenous administra-
tion of tetrahydrocannabinol (THC) to healthy participants 
induces positive (Barkus et  al., 2011) and negative psy-
chosis-like symptoms (Morrison and Stone, 2011). A wide 
range of animal and human research suggests that the use 
of cannabis during adolescence prompts psychosis and 
cognitive impairment (Ehrenreich et al., 1999; Arseneault 
et al., 2002; Schneider and Koch, 2003). However, there is 
a lack of causal evidence to show that increased cannabis 
use over time also increases the incidence of schizophre-
nia (Moore et al., 2007). Nevertheless, cannabis use may 
exacerbate symptoms of schizophrenia and increase the 
risk of predisposed individuals developing schizophrenia 
(Degenhardt et al., 2003).
Prior review articles 
in  schizophrenia and cannabis
Here, we discuss prior reviews on the relationships 
between cannabis and schizophrenia and novel 
approaches we are taking in our review. Radhakrishnan 
et  al. (2014) conducted a literature review and have 
posited that acute exposure to cannabinoids can produce 
a full range of symptoms including psychophysiologi-
cal irregularities and cognitive deficits. Further, these 
impairments and deficits would appear to be analogies to 
symptoms of schizophrenia. The review also found that 
cannabis can have negative consequences on pre-existing 
psychosis, triggering relapse and exacerbating symptoms 
(Radhakrishnan et al., 2014). Radhakrishnan et al. (2014) 
further suggested that the majority of users who consume 
cannabis do not experience any kind of psychosis, and 
the relationship between cannabinoids and psychosis 
fulfills many but not all of the traditional criteria for cau-
sality. Taking into consideration the above information, 
it is questionable that there is a single causative factor. 
Further, Konings et al. (2012) suggest that childhood mal-
treatment regulates the interaction between psychosis 
and cannabis in an extra-linear, dose-dependent manner. 
Konings et al. (2012) further suggest that self-medication 
is also unlikely to account for the interaction between can-
nabis use and psychosis.
It has been reported that there is a four-fold increase 
in the rates of cannabis use over the last 40 years (Zammit 
et  al., 2008), yet this has not resulted in an increase in 
prevalence of schizophrenia. Further, there is disagree-
ment whether schizophrenia is on the decrease or increase 
(Hickman et  al., 2007). The inconsistency between the 
recent changes in the rates of cannabis consumption and 
relative stability of schizophrenia prevalence may be a 
reflection of schizophrenia being a very heterogeneous 
illness, encompassing multiple sub-types. Rounsaville 
(2007) posits that cannabis-induced psychotic disorder is 
a specific subtype of the schizophrenia spectrum. Further, 
it may have to do with the specific psychoactive ingredi-
ents of the cannabis plant.
The main psychoactive ingredient of the cannabis 
plant is D-9-THC. In healthy individuals and non-schiz-
ophrenia patients, D-9-THC can impair the memory as 
well as induce anxiety and psychotic symptoms (D’Souza 
et al., 2005). Further, it has been found that D-9-THC can 
impair psychomotor control (Ramaekers et al., 2006). In 
contrast, schizophrenia patients exposed to D-9-THC may 
experience exacerbated existing memory impairments, 
anxiety, and psychotic symptoms (D’Souza et  al., 2005). 
Furthermore, D-9-THC is thought to be the psychoactive 
ingredient most likely to be responsible for the increased 
risk of developing schizophrenia following regular canna-
bis use (Moore et al., 2007).
Interestingly, cannabis had another major psychoac-
tive ingredient known as cannabidiol (CBD) which is has 
been found to have no negative impairments on memory 
or other cognitive functions (Fadda et al., 2004; Ilan et al., 
2005). Further, it is believed that CBD possesses antipsy-
chotic properties (Zuardi et al., 1982; Morgan and Curran, 
2008).
Bhattacharyya et al. (2010) found, using fMRI scans on 
participants, that D-9-THC and CBD had opposite activation 
directions in the context of a series of tasks that engaged a 
diversity of brain regions and cognitive processes, specifi-
cally, attenuation of striatal activation by D-9-THC and the 
opposite effect of CBD suggesting inhibition and facilita-
tion of the recall responses (Bhattacharyya et  al., 2010). 
Further, the opposite effects of D-9-THC and CBD found on 
the amygdala activation during fear processing are consist-
ent with the notion of exacerbating and reducing pre-exist-
ing anxiety symptoms (Bhattacharyya et al., 2010).
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Bhattacharyya et al. (2010) reported that D-9-THC had 
concurrent effects on psychotic symptoms while CBD had 
no effect on psychotic symptoms. These findings appear 
to be consistent with that of Zuardi et al. (1982) who sug-
gested that CBD may only have antipsychotic effects in 
patients with pre-existing psychotic symptoms. Further, a 
systematic literature review was conducted, finding con-
current results which suggested that CBD appears to have 
the ability to counteract psychotic symptoms and cogni-
tive impairment and psychosis associated with cannabis 
use (Iseger and Bossong, 2015).
It should be noted that the results of this study have 
their limitations. Firstly, the administration of the active 
D-9-THC and CBD were administered orally or intrave-
nously, and it is unclear if delivery system of the ingredi-
ents will have any effects on the results. Secondly, while 
isolating D-9-THC and CBD, it would seem prudent to 
measure the interplay of all psychoactive ingredients 
of the cannabis plant to account for any compounding 
effects that may confound the above results when can-
nabis is used recreationally. Thirdly, the sample size for 
this study was quite small, and the results should be inter-
preted with caution.
Degenhardt et  al. (2003) posit that changes in the 
occurrence of cannabis use may potentially alter the age of 
onset, number of incidence, and prevalence of psychosis. 
However, Degenhardt et al. (2003) trend model suggested 
that it is unlikely that cannabis had caused psychosis that 
would not otherwise have occurred, however, the first 
episode psychosis cases who used cannabis were younger 
than non-users (Degenhardt et al., 2003). Further, the data 
suggested that it is likely that cannabis use would cause 
relapses to psychosis (Degenhardt et al., 2003), which is 
not consistent with other studies (Bhattacharyya et  al., 
2010). It should be noted that modeling of any trends 
holds its limitations as it is based on assumptions not 
 otherwise empirically tested.
Further, it is well known that schizotypal personality 
disorder (SPD) traits have been found to be more preva-
lent in relatives of schizophrenia patients (Appels et al., 
2004) and that they typically share similar genetic traits 
to schizophrenia patients (Fanous et  al., 2007). Further, 
individuals with SPD commonly exhibit social deficits 
less prominent than but similar to schizophrenia (Dickey 
et  al., 2005). Previous studies have examined cannabis 
use as a correlate of SPD and its associated dimensional 
traits thought to contribute to risk for psychosis in order 
to explore the affiliation between psychotic symptoms 
and cannabis use. Numerous studies have found asso-
ciations between cannabis use and positive schizotypal 
features (Barkus and Lewis, 2008; Esterberg et al., 2009; 
Najolia et al., 2012). However, it should be noted that these 
studies predominately studied university students using 
self-report measures which may have confounded the 
results of the above mentioned studies.
Furthermore, it has been found that there is a sig-
nificant positive correlation between schizotypy scores 
and cannabis use (Skosnik et  al., 2001) as well as an 
association between cannabis use and negative, dis-
organized, and positive schizotypal traits (Bailey and 
Swallow, 2004). It has been posited that these results 
indicate that the risk of SPD and associated psychosis 
increases with greater use of cannabis, and compared 
to non-users, greater cannabis use showed significantly 
increased risk of SPD symptoms (Davis et  al., 2013). 
However, much like the research with schizophrenia 
patients and cannabis, there is some controversy as it 
has also been shown that cannabis is associated with 
lower negative schizotypal traits in users than in non-
users (Schiffman et al., 2005).
Alongside SPD, schizoaffective disorder is also related 
to schizophrenia as both disorders have been placed 
under the ‘Schizophrenia Spectrum and Other Psychotic 
Disorders’ section of DSM-5. Schizoaffective disorder com-
monly presents with features of schizophrenia taking 
place concurrently with a mood episode (Malaspina 
et  al., 2013). Further, there is a significant similarity in 
the genes contributing to SPD, schizoaffective disorder, 
and schizophrenia (Cardno and Owen, 2014). It has been 
found that there is a strong comorbidity between schiz-
oaffective disorder and CUD (Koskinen et  al., 2010), as 
similar to SPD and schizophrenia. Further, the literature 
would suggest that cannabis usage is correlated with sig-
nificantly lower quality of life, impacting negatively on 
patients with schizoaffective disorder (Foti et  al., 2010). 
However, it should also be noted that it has been found 
that cannabis use is correlated with improved quality of 
life presenting in relief from side effects of antipsychotic 
medications and psychiatric symptoms, depression, and 
boredom (Goswami et  al., 2004). It is clear that there is 
much controversy in our current understanding of can-
nabis use and its effect on the schizophrenia spectrum 
and other psychotic disorders and that further research is 
required to resolve existing conflicting results.
Cannabis, schizophrenia, and 
cognition
While research reliably illustrates cognitive impairment 
of specific cognitive domains as a common symptom 
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expression of schizophrenia, findings on the effects of can-
nabis use are varied. In contrast to the healthy, non-diag-
nosed population, it is mainly agreed upon that cannabis 
users have yielded poorer neuropsychological function-
ing and have comparable cognitive performance between 
users and non-users (Pope et al., 2001). This being said, 
there have been research findings both consistent and 
inconsistent with the common cognitive impairment with 
schizophrenia patients. It has been found that approxi-
mately 80% of patients that used cannabis presented with 
more exacerbated and global deficits across cognitive 
domains. However, it has also been reported that schizo-
phrenia patients with a history of cannabis use have less 
severe cognitive deficits (Stirling et al., 2005).
Regardless of agreement on cognitive deficit, the mod-
erating character of cannabis use on cognitive domains 
such as special abilities, memory and learning, attention, 
and intelligence remains unclear. Interestingly, cannabis 
use has been correlated with higher rates of psychotic 
symptoms and aberrant brain functioning (D’Souza et al., 
2005) and is thought to hinder prognosis (Linszen et al., 
1994). These findings suggest that cannabis may have dif-
ferential effects on a susceptible schizophrenia user as 
compared to a healthy non-diagnosed user.
Very little is known about the cognitive function of 
patients suffering from the combined effects of schizo-
phrenia and cannabis use. To date, there have been 
inconsistent findings of the effects of cannabis on neu-
rocognition. In the current literature, there are studies 
examining the effects of cannabis use on cognition in 
schizophrenia that have found superior neuropsychologi-
cal functioning (Schnell et al., 2009), while other studies 
have observed poorer cognitive performance (Mata et al., 
2008). Further, some studies were unable to find a signifi-
cant difference in some cognitive tasks when comparing 
patterns of cannabis use among schizophrenia patients 
(Jockers-Scherübl et al., 2007; Sevy et al., 2007).
Yucel et  al. (2012) conducted a meta-analysis with a 
focus on the effects of cannabis on cognition in schizo-
phrenia patients. The inclusion criterion for this meta-
analysis was whether the most preferred substance of the 
sample was cannabis. As a result, this analysis included 
studies where not all patients in the substance-using 
group were abusing cannabis, and as such, the findings 
of the cannabis-using subgroup were confounded by con-
current drug use.
Rabin et  al. (2011) also conducted a meta-analysis 
researching the neurocognition in schizophrenia patients 
with no other current comorbid substance use. The 
results suggested a significant superior neurocognitive 
performance in cannabis-using schizophrenia patients 
compared to non-using schizophrenia patients. However, 
Rabin et al. were not able to determine effect size differ-
ences due to psychotic diagnosis, the combined effects of 
cannabis use and schizophrenia, nor the effects of canna-
bis use alone.
Cannabis, schizophrenia, and 
positive and negative symptoms
Further, there is disagreement on the effects of cannabis 
on both positive and negative symptoms in schizophrenia 
patients. There are findings not only to support elevated 
levels of positive symptoms in comparison to non-user 
schizophrenia patients without cannabis use (Degenhardt 
et al., 2007), although other studies found no difference 
in positive symptoms (Green et al., 2004). Similarly with 
negative symptoms, there is evidence to support no differ-
ence between schizophrenia patients who used and those 
who did not use cannabis (Stirling et  al., 2005), as well 
as evidence to support decreased levels of negative symp-
toms (Koskinen et al., 2009) in schizophrenia user versus 
non-user patients. In 2008, Potvin et al. (2008) conducted 
a meta-analysis to determine to which extent better neu-
ropsychological functioning might be found among 
patients with schizophrenia and substance use disorders. 
Potvin et  al. (2008) concluded that these schizophrenia 
patients do not represent a homogeneous group and that 
future investigations should consider intermediate factors 
to define subgroups such as first time or lifelong user and 
drug of choice.
In summary, the association between cannabis and 
psychosis has been established for many years. However, 
it is still misunderstood whether cannabis use is a contrib-
uting cause for psychosis. The current review will briefly 
summarize the nature of the association between can-
nabis use and the development of psychosis and current 
thinking on the underlying neurobiology for their interac-
tion. This will help provide a better understanding of the 
links between cannabis use and schizophrenia. An addi-
tional goal of the present paper is to propose possible pre-
vention opportunities in the target population especially 
cannabis users.
The endocannabinoid system
Cannabis is one the most widely used illicit substances 
in the Western world (Smart and Ogborne, 2000; Von 
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Sydow et al., 2001) and one of the oldest used drugs with 
almost 60 different cannabinoids. Among many psycho-
active chemicals in cannabis, the most active substance in 
cannabis is Δ9-trans-THC (Gaoni and Mechoulam, 1971). 
The endocannabinoid system (ECS) was discovered in 
the early 1990s and is composed of cannabinoid recep-
tors (CB1 and CB2), ligands (anandamide), and protein for 
synthesis and degradation (Ameri, 1999; Pertwee, 2006; 
De Petrocellis and Di Marzo, 2010). ECS is widely distrib-
uted throughout the human body and affects immune 
response, learning, pain, body temperature, motor co-
ordination, apoptosis, and others. Furthermore, the ECS 
malfunctions in schizophrenia patients, with impaired 
CB1 functions (Ameri, 1999), altered densities (Dean et al., 
2001), gene polymorphism (Leroy et  al., 2001), elevated 
anandamide ligand level in cerebrospinal fluid (Leweke 
et al., 1999; Giuffrida et al., 2004), and altered CB1. In light 
of this, there is a strong tie between cannabis and psycho-
sis (D’Souza et  al., 2005). For example, schizophrenia 
patients have more psychotic relapses and hospitalization 
with cannabis abuse (Linszen et  al., 1994). Schizophre-
nia patients also experience a two- to three-fold increase 
in psychotic symptoms (Arseneault et  al., 2002; Semple 
et  al., 2005) including positive symptoms and negative 
symptoms (Solowij and Grenyer, 2002). Furthermore, can-
nabis affects cognitive functions, such as selective atten-
tion in patients with schizophrenia (Emrich et  al., 1997; 
Pope et al., 2001).
The reasons for the interplay between schizophrenia 
symptoms and cannabis use remain unclear. One possi-
ble explanation is dopamine sensitization in schizophre-
nia (Moghaddam and Krystal, 2003); this makes patients 
more sensitive to the effects of cannabis (Chambers and 
Self, 2002; Tsiridis et al., 2003). Another explanation may 
be disturbance in the ECS (Potvin et al., 2008). A wealth of 
evidence supports the hypothesis that dysfunction of the 
cerebral ECS may be involved in the pathology of schizo-
phrenia (for review, see Ujike and Morita, 2004; Barnes 
et al., 2006).
Cannabis-schizophrenia interplay 
in animal models
There is mounting evidence that the underlying patho-
physiology in schizophrenia involves impairment in 
dopamine, glutamine, and acetylcholine (Moghaddam 
and Krystal, 2003). Surprisingly, these neurotransmit-
ters stimulate N-arachidonoylethanolamine synthesis 
and release in rodents (Leweke et  al., 1999; Stella and 
Piomelli, 2001). There are many available animal models 
which study schizophrenia, with pros and cons for each 
one. The weakness of most available models is that they 
are either not developmental or not consistent with the 
neuropathology of the disorder (Harrison and Eastwood, 
2001; Tunbridge et al., 2004). There have only been a few 
studies that analyze addiction using rodent models of 
schizophrenia, which have varied from in vitro analyses 
(Rodvelt et  al., 2008a,b), to sensorimotor gating (Radek 
et al., 2006), to alleviating cognitive impairments (Rezvani 
et al., 2008). Thus, there is a dearth of information regard-
ing addiction’s effects on the brain and behavior using a 
rodent model of schizophrenia.
Animal models of schizophrenia are of paramount 
importance to better understand the pathogenesis of this 
disorder. This is due to the difficulty in controlling the 
complex nature between genetics and environment in 
clinical studies (Calvigioni et al., 2014). An ideal animal 
model is able to recapitulate the pathology and progres-
sion of the disease (Langer and Halldin, 2002). Several 
pharmacological models exist that could introduce some 
feature of schizophrenia; these include models affecting 
serotonergic, glutamatergic, GABAergic, dopaminergic, 
and opioid systems (Steeds et al., 2015). However, in this 
review we will focus on animal models manipulating the 
cannabinoid system.
The first models of cannabinoid manipulation were 
induced through THC which is the primary active com-
ponent of cannabis. THC administration to rodents led 
to an impairment of memory functions and impaired pre-
pulse inhibition coupled to persistent behavioral changes. 
These effects were controlled by antipsychotic therapy 
administered to the animals (Schneider and Koch, 2003; 
Rubino et al., 2008; Realini et al., 2009).
More recently, animal models were induced to study 
the impact of cannabis use in adolescence (Hutchings and 
Dow-Edwards, 1991). Some of these models showed some 
schizophrenia-related behavioral abnormalities (Malone 
et al., 2010). This was attributed to cannabis affecting the 
maturational change that normally occurs in the endo-
cannabinoid system during adolescence (Rubino and 
Parolaro, 2015). Furthermore, animal models support the 
interplay between genetic predisposition and environ-
mental exposure to cannabis. Tantra et al. (2014) revealed 
that chronic exposure of juvenile St8sia2−/− mice to Δ9-THC 
affects learning and memory, which is contrary to wild 
type mice exposed to the same regimen.
The effect of prenatal exposure to cannabis has also 
been investigated to further understand the interplay 
between cannabis use and schizophrenia. An animal 
study showed that prenatal exposure to THC led to 
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ultrasonic vocalization of rat offspring, which is similar 
to human earlier fetal distress (Trezza et al., 2008). More 
interestingly, parental germline exposure to cannabis led 
to molecular changes in offspring striatum denoting that 
fetal development may be affected through prenatal expo-
sure, either from germline transmission or direct exposure 
during pregnancy (Szutorisz et  al., 2014). Nevertheless, 
animal models offer a unique opportunity to study the 
impact of cannabis on schizophrenia not only as a con-
tributory or protective agent but also as provider of insight 
into the differential response to cannabis in patients with 
schizophrenia. Recently, Gallo et al., studied this problem 
using neonatal ventral hippocampus lesions in rats (Gallo 
et  al., 2014). Both THC and WIN55, 212-2 (a cannabinoid 
receptor agonist) were used. In general, they showed that 
adult schizophrenic animals were differentially respon-
sive to cannabis motivational effects. Most animal studies 
focused on the contributory role of cannabinoids in induc-
ing schizophrenia or similar effects in studied animals. 
However, others proposed cannabis as a potential therapy 
for some schizophrenic manifestations. Spano et al. (2013) 
showed that cannabinoid self-administration attenuated 
the psychotomimetic effects of phencyclidine in rats. 
Based on these results, cannabis may exert protective 
effects on positive schizotypic manifestations in animal 
models. As can be seen, animal models will contribute 
largely to our understanding of schizophrenia pathogen-
esis and treatment and to identify the negative and posi-
tive aspects of cannabis use in schizophrenia.
Cannabis-schizophrenia interplay 
in humans
There are many hypotheses that explain the high preva-
lence of cannabis use among patients with schizophrenia. 
The self-medication hypothesis assumes that patients 
consume cannabis to alleviate their symptoms and reduce 
unpleasant secondary effects of their medications (Awad 
and Voruganti, 2015). There is no empirical support for 
this hypothesis, given that cannabis aggravates rather 
than improves psychotic symptoms. On the other hand, 
others show that the ECS is dysregulated in schizophre-
nia with different sensitivity to the psychoactive effects 
of cannabis (Muller-Vahl and Emrich, 2008; Potvin et al., 
2008).
Studies found that in healthy populations, canna-
bis use can cause paranoia, hearing voices, and schizo-
phrenia. Such reports of the link between cannabis use 
and schizophrenia were found in different countries 
including the US, UK, Australia, South Africa, India, 
Sweden, and Pakistan. Other studies also found that can-
nabis use can also lead to psychotic episodes in patients 
with schizophrenia (Negrete et  al., 1986); these effects 
were found to be related to the dose of cannabis taken. 
The link between cannabis use and schizophrenia was 
also reported in a longitudinal study with Swedish con-
scripts (Zammit et al., 2002). One limitation of this study 
(as well as most other studies) was the reliance on self-
reports and failure to collect urine samples to identify 
cannabis use and dosage. Another longitudinal study 
found that cannabis use at a younger age increased the 
risk of developing schizophrenia than drug use at an 
older age (Arseneault et al., 2002). Furthermore, there is 
attentional dysfunction in patients with schizophrenia 
who use cannabis simultaneously along with sensory 
cortical circuit affection.
The exact biological link between cannabis use and 
schizophrenia is not clear (Shrivastava et al., 2014). Some 
studies suggested that changes to dopamine and endocan-
nabinoid receptors play a role. At the biological level, the 
active component in cannabis (i.e. THC) activates endo-
cannabinoid receptors as well as increases presynaptic 
dopamine in different cortical areas. Further, it has been 
reported that schizophrenia is associated with changes to 
both dopamine and endocannabinoid receptor structure 
and function.
Although the incidence of schizophrenia among can-
nabis users is higher than in the general population, it 
is still unknown what factors or individual differences 
make some but not others develop psychosis and schiz-
ophrenia. One study, however, found that current daily 
use and consuming cannabis for more than 5 years was a 
strong predictor for having schizophrenia symptoms. It is 
also not known whether there are personality traits that 
may be risk factors for both cannabis use and schizophre-
nia, so it is not known if the link between cannabis use 
and schizophrenia is causal or not. Future studies should 
also test whether schizophrenia symptoms can persist 
after drug use abstinence. Further, given that most drug 
users often consume more than one kind of drug, it is not 
unlikely that other drugs of abuse (e.g. amphetamines, 
cocaine, or others) may cause hallucinations and psy-
chosis and eventually schizophrenia. This is supported 
by a recent study showing that poly drug use is more 
associated with schizophrenia than cannabis use alone 
(Rognli et  al., 2015). Furthermore, there are many risk 
factors associated with schizophrenia besides cannabis 
use, including urbanicity, comorbidity with other psy-
chiatric disorders, and genetic factors. Future research 
should attempt to reveal which of these are the strongest 
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predictors of schizophrenia and whether these factors 
impact cannabis use.
Interactions between stress, 
cannabis use, and schizophrenia
Many studies show a link between cannabis use, stress, 
and schizophrenia. These links are greater in vulnerable 
populations (e.g. those exposed to childhood abuse) who 
have a family history of schizophrenia. Konings et  al. 
(2012) found that childhood abuse moderated the effect of 
cannabis use on psychosis in a dose-dependent manner. 
The severity and frequency of abuse moderated the 
relationship between cannabis use and psychosis. Indi-
viduals who were subjected to sexual or physical abuse 
during childhood or early adolescence experienced an 
increase in the psychotic effects of cannabis. This dem-
onstrated that cannabis use and childhood abuse can 
lead to symptoms of psychosis. Other studies have also 
found that childhood abuse can lead to the development 
of schizophrenia or trigger its onset in vulnerable popula-
tions. Konings et al. (2012) suggested that this interaction 
was probably not due to self-medication. Indeed, Coug-
nard et al. (2007) found that cannabis use, the stressors 
of childhood trauma, and coming from an urban area 
combined additively to produce increased psychotic 
symptoms in subjects both with and without baseline 
psychotic symptoms. The risk of psychotic experience 
was increased by the interaction between cannabis and 
adverse childhood experience, in a more than additive 
fashion (Harley et al., 2010). Along these lines, Houston 
et al. (2008) reported that teenagers who used cannabis 
under 16 years of age, combined with sexual abuse also 
under 16, had a 12 times greater risk for psychosis. It is 
important to note that a majority of these studies do not 
demonstrate a causal relationship. Nor have they identi-
fied whether the interaction between cannabis use and 
childhood resulted in the development of new psychotic 
symptom or the maintenance of current psychotic symp-
toms. As such, further exploration of the causal relation-
ship between stress (e.g. childhood abuse), cannabis use, 
and schizophrenia is needed.
The concept of sensitization has been introduced 
to explain the additive effect of cannabis and stress 
on schizophrenia, whereby the repeated use of canna-
bis, particularly in adolescence when brain structures 
are being formed, may lead to an overreaction of the 
dopamine system (Cougnard et  al., 2007). In an animal 
study, MacLean and Littleton (1977) reported that the 
administration of THC to rats experiencing stressful con-
ditions changed dopamine metabolism in the corpus stri-
atum. THC administration affects the endocannabinoid 
receptor CB1  which influences limbic system dopamine 
release (Cougnard et al., 2007). Levels of cortisol (the main 
hormone involved in the stress response) increase with 
stress and affect dopamine metabolism (Cougnard et al., 
2007). The hypothalamic-pituitary-adrenal axis which is 
involved in the response to stress is partially regulated by 
the endocannabinoid system (Appiah-Kusi et al., 2015). It 
is plausible that cannabis use affects the stress response 
through its effect on the endocannabinoid system. On the 
other hand, Habets et al. (2011) argue that dopamine sen-
sitization in schizophrenia, caused by repeated stress and 
cannabis use, may operate through the effects of reduced 
cortical thickening. The physiological condition underly-
ing the interaction between stress and cannabis use is not 
known for sure. However, Mizrahi et  al. (2014) propose 
that genetic vulnerability combines with stressors and/or 
drugs to produce psychosis.
Discussion
The link between cannabis use and schizophrenia is mul-
tifaceted and partially comprehended. It is well known 
that cannabis abuse is a risk factor for mental illness 
(McGee et al., 2000; Rey et al., 2002) especially psycho-
sis (for a review, see Henquet et al., 2005; Radhakrishnan 
et al., 2014; Wilkinson et al., 2014).
The use of cannabis is not only related to psychotic 
patients (Ringen et al., 2008) but also increases the risk 
for schizophrenia (Moore et  al., 2007; Manrique-Garcia 
et al., 2012). A wealth of evidence has demonstrated the 
role of the ECS in the pathophysiology of schizophrenia 
(Leweke et  al., 2007; Morgan et  al., 2013). Furthermore, 
there is evidence that alteration of the ECS plays a vital 
role in cannabis use (Realini et al., 2009) and schizophre-
nia (Muller-Vahl and Emrich, 2008; Koethe et al., 2009). 
Additionally, some of the neurocognitive impairments in 
cannabis users are similar to those observed in patients 
with schizophrenia (Solowij and Michie, 2007; Cohen 
et  al., 2008; Gallinat et  al., 2012). Paradoxically, there 
is growing evidence that cannabis use in patients with 
schizophrenia improves cognitive functions (Segev and 
Lev-Ran, 2012) and negative symptoms (DeRosse et  al., 
2010; Gorynia et al., 2014). Likewise, patients with schizo-
phrenia who are cannabis users show less severe deficits 
in frontal gray matter compared to naïve first-episode 
patients with schizophrenia (Schnell et  al., 2012). From 
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a clinical perspective, it is uncertain that the aforemen-
tioned findings associated with cannabis use in patients 
with schizophrenia are indeed specific to schizophrenia 
per se (Rentzsch et al., 2011; Wobrock et al., 2013).
It remains to be explored if any advantageous effects 
of ECS stimulation in the perspective of schizophrenia 
will prove to be of practical therapeutic value. Robson 
et al. (2014) investigated the therapeutic prospects of can-
nabinoids in schizophrenia. They concluded that can-
nabinoid medicine might have the potential to reduce 
the unwanted side effects of antipsychotic drugs and 
help control the associated metabolic problem, which is 
a part of the schizophrenia phenotype. Indeed, many of 
the potential side effects associated with cannabis use 
(e.g. psychosis) are attributed to the high levels of THC 
in recreational cannabis. Specifically, the acute admin-
istration of THC can cause schizophrenic like symptoms 
and cognitive impairments (Radhakrishnan et  al., 2014; 
Iseger and Bossong, 2015) as well as increase the severity 
of symptoms in patients with schizophrenia. Conversely, 
there is mounting evidence that cannabinoids (CBD; the 
other main compound in cannabis) can counter these 
effects and have potential therapeutic applications for 
treating, or at least lowering, the risk of psychosis, cogni-
tive impairments, anxiety, and euphoria (Bhattacharyya 
et al., 2010) as well as anti-inflammatory and neuropro-
tective properties. However, these effects are only promi-
nent when the levels of CBD are higher than the THC 
levels in the cannabis. It is noteworthy that 5 and 10 year 
mortality risk in patients with schizophrenia was sig-
nificantly lower in those who regularly smoked cannabis 
compared with non-cannabis patients (Koola et al., 2012). 
Such beneficial effects may be due to cognitive functions 
improvement, metabolic parameters improvement, and/
or reduced stress. All these postulated hypotheses are 
equally plausible and accepted. However, these hypoth-
eses are in need of replication and extension for their 
validity and to identify the effectiveness of CBD compared 
to antipsychotic drugs already in use.
Clinical implications and future 
directions
Schizophrenia is a common psychiatric disorder all over 
the world. Currently, there is no available laboratory 
test to diagnose schizophrenia, but instead, diagnosis 
depends mainly on the patients’ symptomatology and 
the clinicians’ observations. There are many possible 
combinations of symptoms for schizophrenia, and thus 
there is a debate whether schizophrenia is a single dis-
order or a number of discrete syndromes (Tandon et al., 
2008). Hence, behavioral and neurobiological marker 
studies will provide important information about the 
neuroplastic changes associated with cannabis abuse in 
patients with schizophrenia. Gaining a greater insight 
into the mechanisms of cannabis dependence in patients 
with schizophrenia will lead naturally to the develop-
ment of pharmacotherapeutics and identifying objective 
laboratory tests for the diagnosis of schizophrenia. This 
knowledge may also aid cannabis cessation for indi-
viduals with schizophrenia as well as addicts without 
schizophrenia who express similar changes in choliner-
gic function.
It is clear that there is controversy in the current lit-
erature on cannabis effects on schizophrenia patients. 
While some studies have found cognitive deficits (e.g. 
Pope et al., 2001), others have found superior neurocog-
nitive performance (e.g. Rabin et al., 2011) in schizophre-
nia patients who used cannabis. It may be that there is 
a clear lack of consistency when studies proceduralize 
and categorize the ‘user’ versus ‘non-user’ criterion to 
account for confounding variables such as frequency, 
amount, duration, and comorbid substances. Further, 
Bornstein et al. (1990) suggest that symptom severity and 
chronicity have to be considered in order to accurately 
examine potential moderators on effect size in cognitive 
functioning in schizophrenia patients. With this in mind, 
it is clear that the above mentioned findings are likely to 
be confounded by uncontrolled variables that can affect 
such factors. Variables such as duration of diagnosis, age 
of initial onset of symptoms, nature of cannabis use, and 
varying psychiatric symptoms need to be considered for 
studies.
Summary and conclusions
This review highlights the main findings in humans and 
animals concerning the effects of combining cannabis 
with schizophrenia. Where possible, one of the aims was 
to elucidate similarities and differences between investi-
gations in humans and those carried out in animals. Our 
major question is does the co-existence of cannabis use 
and schizophrenia increase or lessen risks for compul-
sive use, toxicity, or both? The interaction between can-
nabis use and schizophrenia in rats would seem to bring 
that point into sharp focus. There is no doubt that can-
nabis is one of the most popular illicit drugs because of 
its intense euphoric effects and the accompanying myth 
Brought to you by | University of Szeged
Authenticated
Download Date | 3/7/19 3:17 PM
A.A. Moustafa et al.: Cannabis and schizophrenia      819
about its safety and ability to treat some human disorders. 
Therefore, to better gauge the extent of cannabis use and 
schizophrenia, we must rely on preclinical studies and 
human case reports. Such research should provide clear 
information and, in turn, inform prevention and interven-
tion efforts.
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